US92686J1060
© PR Newswire
12.01.2026
VKTX
LISTED
NASDAQ
Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
News Preview
Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH Phase 3 Registrational Program in ObesitySAN DIEGO, Jan. 12, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focu...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2026
VKTX
LISTED
NASDAQ
Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
News Preview
Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies f...
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2026
VKTX
LISTED
NASDAQ
Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer
News Preview
Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing ExpertiseSAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appo...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
05.01.2026
VKTX
LISTED
NASDAQ
Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation at the 44th Annual J....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
25.11.2025
VKTX
LISTED
NASDAQ
Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference
News Preview
SAN DIEGO, Nov. 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the Piper Sandler 37th Annual Healthcare Conference. The conference will take place...
Themefolio
Profiler
Peergroup
© PR Newswire
19.11.2025
VKTX
LISTED
NASDAQ
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
News Preview
78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity
Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest in VK2735
SAN DIEGO, Nov. 19, 2025 /PRNewswire/ -- Vi...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2025
VKTX
LISTED
NASDAQ
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025
News Preview
VENTURE Study Exploratory Analysis Shows VK2735 Improved Cardiometabolic Parameters After 13 Weeks; Reducing Prediabetes and Metabolic Syndrome
SAN DIEGO, Nov. 6, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking")...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
VKTX
LISTED
NASDAQ
Viking Therapeutics to Participate at Upcoming Investor Conferences
News Preview
SAN DIEGO, Nov. 4, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at two upcoming investor conferences. ...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
VKTX
LISTED
NASDAQ
Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025
News Preview
Poster Presentation on VENTURE Study Results Evaluating Impact of VK2735 on Prediabetes and Cardiometabolic Status
Additional Poster Presentations Scheduled for American Heart Association Scientific S...
Themefolio
Profiler
Peergroup
© PR Newswire
22.10.2025
VKTX
LISTED
NASDAQ
Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Conference call scheduled for 4:30 p.m. ET today
Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Proceeding on Schedule
VK2735 Phase 1 Maintenance Dosing Study Underway...
Themefolio
Profiler
Peergroup
© PR Newswire
21.10.2025
VKTX
LISTED
NASDAQ
Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity
News Preview
Study to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735
Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens to be Evaluated
SAN DIEGO, Oct. 21, 2025 /PRNewswire/ -- Viking...
Themefolio
Profiler
Peergroup
© PR Newswire
15.10.2025
VKTX
LISTED
NASDAQ
Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025
News Preview
Conference Call Scheduled for Wednesday, October 22 at 4:30 p.m. Eastern Time
SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focuse...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
28.08.2025
VKTX
LISTED
NASDAQ
Viking Therapeutics to Participate at Upcoming Investor Conferences
News Preview
SAN DIEGO, Aug. 28, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at multiple upcoming investor conferences. ...
Themefolio
Profiler
Peergroup
© PR Newswire
19.08.2025
VKTX
LISTED
NASDAQ
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
News Preview
Study Achieves Primary and Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight with Once-Daily VK2735 Dosing as Compared to Placebo
Up to 12.2% (26.6 lbs) Mean Weight Loss Observed After 13 Weeks of VK2735 Treatment Compared with 1.3% (2.9 lbs) for Placebo
Exploratory Assessment of Low Dose Maintenance Treatmen...
Themefolio
Profiler
Peergroup
© PR Newswire
23.07.2025
VKTX
LISTED
NASDAQ
Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Conference call scheduled for 4:30 p.m. ET today
Phase 3 VANQUISH Registration Trials Underway for VK2735 in ObesityPhase 2 VENTURE-Oral Dosing Trial Enrollment Completed; Top-Line Results Expected 2H25Continued Progress with Amylin Program; IND Planned 4Q25Strong Quarter-End Cash Position of $808 MillionSAN DIEGO, July 23, 2025 /PRNewswire/ -- V...
Themefolio
Profiler
Peergroup
© PR Newswire
16.07.2025
VKTX
LISTED
NASDAQ
Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025
News Preview
Conference Call Scheduled for Wednesday, July 23 at 4:30 p.m. Eastern Time
SAN DIEGO, July 16, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will re...
Themefolio
Profiler
Peergroup
© PR Newswire
25.06.2025
VKTX
LISTED
NASDAQ
Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
News Preview
VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes
SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announc...
Themefolio
Profiler
Peergroup
© PR Newswire
23.04.2025
VKTX
LISTED
NASDAQ
Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Conference call scheduled for 4:30 p.m. ET today
Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully Enrolled; Data Expected 2H25Broad Manufacturing Agreement with CordenPharma to Support Future Commercialization of VK2735Strong Quarter-End Cash Position of $852 MillionSAN DIEGO, April 2...
Themefolio
Profiler
Peergroup
© PR Newswire
16.04.2025
VKTX
LISTED
NASDAQ
Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025
News Preview
Conference Call Scheduled for Wednesday, April 23 at 4:30 p.m. Eastern Time
SAN DIEGO, April 16, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release fi...
Themefolio
Profiler
Peergroup
© PR Newswire
26.03.2025
VKTX
LISTED
NASDAQ
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
News Preview
13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily
Results Expected in 2H25
SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the...
Themefolio
Profiler
Peergroup
© PR Newswire
11.03.2025
VKTX
LISTED
NASDAQ
Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735
News Preview
Long-Term Agreement Secures Dedicated Capacity for Multi-Ton Annual Supply of VK2735 Active Pharmaceutical Ingredient
Secures Dedicated Fill/Finish Capacity for 100 Million Annual Autoinjector Supply and Additional 100 Million Annual Vial/Syringe Supply
Provides Annual Capacity of Over 1 Billion Oral Tablets
Viking to Make Prepayments Totaling $...
Themefolio
Profiler
Peergroup
© PR Newswire
04.03.2025
VKTX
LISTED
NASDAQ
Viking Therapeutics to Participate at Upcoming Investor Conferences
News Preview
SAN DIEGO, March 4, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at multiple upcoming investor conferences. ...
Themefolio
Profiler
Peergroup
© PR Newswire
05.02.2025
VKTX
LISTED
NASDAQ
Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
News Preview
Conference call scheduled for 4:30 p.m. ET today
Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25Phase 2 VENTURE-Oral Dosing Trial Evaluating VK2735 in Obesity UnderwayStrong Year-End Cash Position of $903 MillionSAN DIEGO, Feb. 5, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinic...
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2025
VKTX
LISTED
NASDAQ
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025
News Preview
Conference Call Scheduled for Wednesday, February 5 at 4:30 p.m. Eastern Time
SAN DIEGO, Jan. 29, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release f...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2025
VKTX
LISTED
NASDAQ
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
News Preview
13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily
SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 2 c...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2025
VKTX
LISTED
NASDAQ
Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
News Preview
SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation at the 43rd Annual J...
Themefolio
Profiler
Peergroup
© PR Newswire
19.11.2024
VKTX
LISTED
NASDAQ
Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
News Preview
Oral Late Breaker Presentation Summarizes Positive Results Including Successful Achievement of Study's Primary and Secondary Endpoints
Data Support VK2809's Best-in-Class Profile Highlighted by Robust Liver Fat Reductions, Histologic Results Demonstrating NASH/MASH Resolution and Fibrosis Improvement, and Promising Tolerability and Safety
SAN DIE...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2024
VKTX
LISTED
NASDAQ
Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
News Preview
Results to be Featured in Oral Late Breaker Presentation
SAN DIEGO, Nov. 12, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that results from the company's Phase 2b clinical tri...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2024
VKTX
LISTED
NASDAQ
Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024
News Preview
Up to 6.8% Placebo-Adjusted Mean Weight Loss (8.2% from Baseline) After 28 Days of Dosing with Oral Tablet of VK2735
Encouraging Tolerability Through 100 mg Daily Dosing with Oral VK2735; Mild GI-Related Adverse Event Profile
Updated Results from VENTURE Phase 2 Study of Subcutaneous VK2735 Show Durable Effects and Support Potential Monthly Do...
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2024
VKTX
LISTED
NASDAQ
Viking Therapeutics to Participate at Upcoming Investor Conferences
News Preview
SAN DIEGO, Oct. 31, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at several upcoming investor conferences. ...
Themefolio
Profiler
Peergroup
© PR Newswire
28.10.2024
VKTX
LISTED
NASDAQ
Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2024
News Preview
Results from VENTURE Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral VK2735 in Healthy Subjects to be Presented
SAN DIEGO, Oct. 28, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and en...
Themefolio
Profiler
Peergroup
© PR Newswire
23.10.2024
VKTX
LISTED
NASDAQ
Viking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
News Preview
Conference call scheduled for 4:30 p.m. ET today
End-of-Phase 2 Meeting for Subcutaneous VK2735 for Obesity Planned for 4Q24Phase 2 Study of Oral VK2735 in Obesity Expected to Begin 4Q24Results of Phase 2b VOYAGE Study of VK2809 in NASH/MASH With Fibrosis Selected for Oral Presentation at AASLDPositive Phase 1b Results from VK0214 Study in X-ALD...
Themefolio
Profiler
Peergroup
© PR Newswire
09.10.2024
VKTX
LISTED
NASDAQ
Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD
News Preview
Reductions in Very Long-Chain Fatty Acids and Plasma Lipid Levels Observed After 28 Days of Once Daily Dosing
VK0214 Shown to be Safe and Well-Tolerated in 28-Day Study
SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapie...
Themefolio
Profiler
Peergroup
© PR Newswire
28.08.2024
VKTX
LISTED
NASDAQ
Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference
News Preview
SAN DIEGO, Aug. 28, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will be the featured speaker in a fireside chat at the Mo...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
